Overview A Phase 1 Study of CLYM116 in Normal Healthy Volunteers Status: NOT_YET_RECRUITING Trial end date: 2026-09-01 Target enrollment: Participant gender: Summary This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.Phase: PHASE1 Details Lead Sponsor: Climb Bio, Inc.